Key result
Tyrosine kinase inhibitors induced drug-selective transcriptomic signatures in hiPSC-derived cardiomyocytes, identifying alterations in energy metabolism and contractile dynamics associated with cardiotoxicity.
Why the study?
Drug-induced gene expression profiles can identify potential mechanisms of toxicity, motivating obtaining signatures for cardiotoxicity of FDA-approved tyrosine kinase inhibitors.
Integrating mRNA expression profiles with genomic and single-cell datasets provides a multiscale predictive understanding of TKI-induced cardiotoxicity.
May inform TKI selection via transcriptomics; leaves open clinical translation from animal models.
Drug-induced gene expression profiles can identify potential mechanisms of toxicity. We focused on obtaining signatures for cardiotoxicity of FDA-approved tyrosine kinase inhibitors (TKIs) in human induced pluripotent stem cell-derived cardiomyocytes. Using bulk transcriptomics profiles, we applied singular value decomposition to identify drug-selective patterns in cell lines obtained from multiple healthy human subjects. Cellular pathways affected by highly cardiotoxic TKIs include energy metabolism, contractile, and extracellular matrix dynamics. Projecting these pathways to single cell expression profiles indicates that TKI responses can be evoked in both cardiomyocytes and fibroblasts. Whole genome sequences of the cell lines, using outlier responses enabled us to correctly reidentify a genomic variant associated with anthracycline cardiotoxicity and predict genomic variants potentially associated with TKI cardiotoxicity. We conclude that mRNA expression profiles when integrated with publicly available genomic, pathway, and single cell transcriptomic datasets, provide multiscale predictive understanding of cardiotoxicity for drug development and patient stratification. One sentence summary Genes, pathways, and cell types of the human heart associated with antineoplastic drug cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2021) studied Cardiotoxicity (n=6). Tyrosine kinase inhibitors (TKIs) and other FDA-approved drugs vs. Untreated control cell lines was evaluated on Drug-selective transcriptomic signatures and pathway activities. Tyrosine kinase inhibitors induced drug-selective transcriptomic signatures in hiPSC-derived cardiomyocytes, identifying alterations in energy metabolism and contractile dynamics associated with cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: